Biotech&Pharma Breakdown: November 3rd, 2025

Five $1 billion+ news last week. Novo just spent $8.5 billion to crash Pfizer's party, the FDA placed CRISPR on pause, and a third of US biotech's workforce wants to leave. Meanwhile, Big Pharma is building AI supercomputers and betting billions on RNA that can cross the blood-brain barrier. This week, the industry's biggest players revealed exactly where they're doubling down and where they're running scared.

GLP-1 And Obesity Wars

Novo's $8.5B counter-offer ignites bidding war for Metsera

On October 30, Novo Nordisk launched a bombshell unsolicited bid for obesity biotech Metsera, offering up to $8.5 billion ($6 billion upfront plus $2.5 billion in development milestones). This effectively hijacked Pfizer's previously announced $7.3 billion acquisition from September.

The move signals just how valuable the obesity franchise has become. Metsera's lead candidate MET-097i, a monthly injectable GLP-1, is expected to reach $5 billion in peak sales by targeting patients fatigued by weekly injections. The global obesity market is projected to hit $150 billion by the early 2030s, and Big Pharma knows it. I also previously covered that GLIP-1 treatments would focus on less injections among other improvements, you can read more here!

Pfizer immediately countersued Novo and Metsera for breach of contract, claiming the bid violates antitrust law through abuse of dominant market position. The outcome will set precedent for how companies compete for transformative obesity assets, and whether Novo's aggressive playbook becomes the new standard.

Lilly navigates the pricing balancing act

Eli Lilly faces a classic pharma dilemma: price orforglipron competitively enough to capture market share while funding next-generation innovation. CEO David Ricks has suggested $100 per month won't sustain R&D pipelines, yet the Trump administration is publicly pushing for obesity medications at $150 per month or lower.

Orforglipron delivered good late-stage results showing 11.2% weight loss, with 54.6% of patients hitting 10% or greater weight loss in the ATTAIN-1 trial. The small-molecule structure means easier manufacturing and no dietary restrictions, clear advantages over injectables.

Lilly is already producing "billions of doses" in anticipation of a 2026 launch and leveraging its LillyDirect self-pay channel, which captured 35% of new Zepbound prescriptions in Q2 2025. The company's direct-to-consumer strategy is their idea to maintain profit and reach more patients.

Walmart partnership signals real democratization of obesity treatment

On October 29, Eli Lilly and Walmart announced that Zepbound single-dose vials will be available for in-store pickup at approximately 4,600 Walmart pharmacies nationwide starting mid-November, with self-pay pricing as low as $349 per month for the 2.5 mg starting dose.

This represents the first time LillyDirect's direct-to-consumer pricing is available via physical retail, not just home delivery. The move undercuts the historical list price of $1,060 and reflects real-world price elasticity as consumers bypass insurance to access proven weight-loss drugs.

More importantly, it signals Big Pharma's strategic shift to change consumer and retail strategy.

Big Pharma Bets And Antibodies

Eli Lilly and Nvidia build pharma's AI supercomputer

On October 28, Eli Lilly and Nvidia announced they would build what they claim is pharma's largest-ever supercomputer, equipped with Nvidia's DGX B300 systems for accelerated drug discovery. The system will train AI models on datasets from millions of Lilly experiments.

Targeting a reduction in discovery timelines from five years to 12-18 months and cutting preclinical development costs by up to 40%, this is not incremental improvement, but a huge bet on computer-based drug discovery. Lilly plans to host select AI models on LillyTuneLab, a federated platform allowing biotech partners to access proprietary models while protecting their own IP.

The supercomputer goes live early 2026 and will handle drug discovery, development, manufacturing optimization, medical imaging, and enterprise AI. It's essentially positioning Lilly as an innovation engine for the next decade of pharma R&D.

Roche licenses Chinese bispecific antibody for respiratory diseases

Roche announced a $1.07 billion deal for QX031N, a bispecific antibody from China's Qyuns Therapeutics targeting both TSLP and IL-33 for COPD and asthma. The mechanism is validated but underserved.

Both TSLP and IL-33 are released by airways in response to allergens, viruses, and pollution. By blocking both alarmins in one molecule, QX031N aims to dampen chronic inflammation—particularly non-type 2 inflammation where treatment options are limited.

Regeneron and ModeX team on multispecific antibodies

Regeneron and OPKO Health's ModeX Therapeutics announced a collaboration to discover and develop multispecific antibodies targeting multiple biological pathways in a single molecule. Regeneron provides proprietary binders that ModeX pairs with its MSTAR platform for immunology, oncology, and metabolic diseases.

ModeX receives $7 million upfront with potential milestones exceeding $200 million per molecule plus tiered royalties. ModeX's trispecific antibody just entered Phase 1/2 testing on October 28.

This collaboration exemplifies the broader "modular antibody" trend. Rather than single binders, pharma is betting on multispecific formats to address disease complexity. Regeneron's antihistamine bispecifics scored Phase 3 wins this month by reducing cat and pollen allergies, validating the entire strategy.

US Regulatory And Workforce Challenges

Intellia's CRISPR program faces FDA clinical hold

On October 29, the FDA placed a formal clinical hold on Intellia's two Phase 3 trials of nex-z, a CRISPR-based therapy for ATTR amyloidosis. The halt followed a safety signal: one patient in the cardiomyopathy trial developed Grade 4 liver enzyme elevation and increased bilirubin, triggering Hy's Law, a hallmark of drug-induced liver injury.

This setback matters because CRISPR therapies for ATTR face direct competition from approved siRNA and antisense oligonucleotide therapies that have already proven safety and efficacy. The formal FDA hold means Intellia must formally respond to FDA communications and provide additional safety data before trials restart.

Brain drain accelerates: one-third of biotech workers exploring international opportunities

BioSpace's latest workforce analysis reveals 32% of biotech employees are actively exploring or considering job opportunities outside the United States, the highest rate since tracking began. This isn't just career development. It reflects both geographic expansion of biotech innovation and ongoing consolidation pressures in the US biotech sector.

Multiple waves of layoffs have accelerated the trend. International biotech hubs, particularly Singapore, Cambridge, and Basel, are actively recruiting US-trained talent with attractive packages and long-term vision.

Deals And Disease Targets

Novartis acquires Avidity in $12B neuroscience play

On October 26, Novartis announced it is acquiring Avidity Biosciences for $12 billion, a $72 per share offer representing a 42% premium. This is the second-largest pharma deal of 2025 after J&J's $14.6 billion Intra-Cellular Therapeutics acquisition.

Avidity's crown jewel is its antibody-oligonucleotide conjugate platform, enabling RNA therapeutics to cross the blood-brain barrier and target muscle tissue with precision. The deal brings three late-stage programs: del-zota for Duchenne muscular dystrophy showing 25% dystrophin increase, del-desiran for myotonic dystrophy type 1, and del-brax for facioscapulohumeral muscular dystrophy.

Notably, Novartis will spin out Avidity's precision cardiology programs into a separate entity retained by current investors. This double bet, both on neuromuscular RNA therapeutics now and the Kate Therapeutics acquisition in November 2024, signals Novartis's conviction that RNA delivery to muscle represents the next frontier in rare disease.

Boehringer and Kyowa Kirin team on preclinical autoimmune molecule

On October 30, Boehringer Ingelheim and Japan's Kyowa Kirin announced a €640 million partnership for a preclinical small-molecule autoimmune program. Details remain limited, but Boehringer disclosed the molecule is "first-in-class" targeting inflammatory pathways relevant to autoimmune diseases.

The deal comprises upfront payment, development milestones, regulatory milestones, commercial milestones, and royalties. This is the companies' second collaboration, reflecting confidence in Kyowa Kirin's immunology pipeline.

GSK licenses COPD siRNA from Empirico

On October 28, GSK announced it is licensing EMP-012, a first-in-class siRNA from Empirico, for $85 million upfront plus up to $660 million in development and commercial milestones with tiered royalties. EMP-012 targets a specific inflammatory pathway in COPD and is already in Phase 1 trials.

Critically, the siRNA addresses non-type 2 inflammation phenotypes, a patient subgroup with limited therapeutic options. This deal reflects GSK's strategy of broadening its COPD portfolio: combining long-acting biologics like approved Nucala with novel small-molecule and oligonucleotide modalities.

The result is treatment across COPD's full spectrum of heterogeneous inflammation. GSK is essentially building a playbook for the multi-modal disease.

BridgeBio's encaleret crushes Phase 3 in calcium deficiency disease

On October 29, BridgeBio announced that encaleret, a small molecule for autosomal dominant hypocalcemia type 1, achieved all primary and key secondary endpoints in its Phase 3 CALIBRATE trial. The results were striking.

76% of encaleret-treated patients achieved target serum and urine calcium levels at Week 24 versus just 4% on standard-of-care. On a key secondary endpoint, 91% achieved normal PTH levels, a marker of restored endocrine function. Encaleret was well-tolerated with no discontinuations.

Mizuho analysts noted the 76% response rate exceeded Phase 2 results. a rare phenomenon where Phase 3 beats Phase 2, signaling robust efficacy. BridgeBio plans NDA submission in H1 2026 and will launch registrational trials in chronic hypoparathyroidism and pediatric ADH1 in 2026.

This win caps an extraordinary week for the company following its Phase 3 success for limb-girdle muscular dystrophy on October 27.

Nanobiotix secures $71M royalty deal, extends runway to 2028

On October 31, French biotech Nanobiotix announced a $71 million non-dilutive royalty financing from HealthCare Royalty: $50 million upfront plus $21 million deferred subject to milestones, extending cash visibility into early 2028. The deal provides critical breathing room for a cash-strapped biotech.

Nanobiotix's lead program JNJ-1900 is a physics-based nanoparticle activated by radiotherapy for solid tumors. Repayment to HCRx is capped at $124-178 million with a $14.9 million per year tail royalty for up to 10 years post-launch.

News From The Forefront Of Science

While M&A dominates headlines, breakthrough research is quietly reshaping therapeutic development. Here are three papers from the past month exemplifying innovation in biotech and pharma.

Novel siRNA chemistry doubles drug durability for triglyceride-lowering therapy

Researchers from Ionis Pharmaceuticals published in Nucleic Acids Research a breakthrough siRNA design featuring 2'-O-MOE and 5'-deoxy-(E)-5'-vinylphosphonate modifications that achieved twice the duration of action compared to plozasiran. The novel APOC3-targeting siRNA maintained 80% plasma apoC3 suppression for up to 8 weeks following a single dose, compared to just 4 weeks for the clinical comparator.

By strategically replacing 2'-fluoro nucleotides with DNA phosphorothioate and 2'-O-methoxyethyl modifications at specific positions, researchers dramatically enhanced metabolic stability without sacrificing potency. This scaffold could enable semi-annual or annual dosing for cardiovascular and metabolic disorders.

That's a game-changer for patient adherence and cost-effectiveness in chronic disease management. Moving from quarterly to annual dosing is a huge change for patients and pharma.

Found this useful? Subscribe and follow for another breakdown next Monday!

TL;DR: Abridged Biotech&Pharma Breakdown, November 3rd, 2025

💰 Novo Nordisk launches $8.5B unsolicited bid for Metsera , hijacking Pfizer 's $7.3B September deal. Monthly GLP-1 MET-097i targets $5B peak sales. Pfizer countersues claiming antitrust violation.

💊 Eli Lilly and Company and Walmart partner to offer Zepbound at 4,600 pharmacies for $349/month starting mid-November. First physical retail presence for LillyDirect pricing model, undercutting $1,059 list price.

🤖 Eli Lilly and Company and NVIDIA build pharma's largest supercomputer with DGX B300 systems. Targets 12-18 month discovery timelines (vs. 5 years) and 40% cost reduction. Live early 2026.

💉 Roche pays $75M upfront (up to $1.07B) for Qyuns Therapeutics' QX031N, dual TSLP/IL-33 bispecific for COPD and asthma. Targets non-type 2 inflammation with limited treatment options.

🧬 Regeneron and ModeX Therapeutics Inc collaborate on multispecific antibodies. $7M upfront, $200M+ milestones per molecule. Trispecific antibody entered Phase 1/2 testing October 28.

🚫 FDA places clinical hold on Intellia Therapeutics, Inc. nex-z CRISPR therapy for ATTR amyloidosis after Grade 4 liver enzyme elevation. Critical test for CRISPR's clinical credibility vs. approved siRNA/ASO competitors.

✈️ BioSpace reports 32% of US biotech employees actively exploring international opportunities, the highest rate ever. Singapore, Cambridge, and Basel recruiting US-trained talent as consolidation pressures accelerate brain drain.

💰 Novartis acquires Avidity Biosciences, Inc. for $12B ($72/share, 42% premium). Antibody-oligonucleotide conjugate platform brings three late-stage neuromuscular programs including del-zota for Duchenne MD.

🫁 GSK licenses Empirico 's EMP-012 siRNA for COPD: $85M upfront, up to $660M milestones. First-in-class asset targets non-type 2 inflammation, already in Phase 1 trials.

🎯 BridgeBio Pharma crushes Phase III CALIBRATE: 76% of patients achieved calcium targets vs. 4% on SOC for ADH1. 91% normalized PTH levels. NDA filing H1 2026. Second win in three days after LGMD success.

💰 Nanobiotix secures $71M royalty financing from HealthCare Royalty : $50M upfront, $21M deferred. Extends runway to early 2028 for JNJ-1900 radiotherapy nanoparticle trials.

🧬 Nucleic Acids Research: Novel siRNA chemistry doubles duration to 8 weeks (vs. 4 for plozasiran) with 80% apoC3 suppression. 2'-O-MOE modifications enable potential semi-annual dosing for cardiovascular disease. Researchers from Ionis Pharmaceuticals, Inc.

Found this useful? Subscribe and follow for another breakdown next Monday!